The stock price of Arvinas (NASDAQ: ARVN), a biopharmaceuticals company focused on oncology treatments based on targeted protein degradation, has fallen 24% in a month, while it’s down a ...

Arvinas, Inc. (ARVN) has been beaten down lately with too much selling pressure. While the stock has lost 54.9% over the past four weeks, there is light at the end of the tunnel as it is now in ...

We recently compiled a list of the 10 Best Small-Cap Healthcare Stocks To Buy Now. In this article, we are going to take a look at where Arvinas, Inc. (NASDAQ:ARVN) stands against the other small ...

A downtrend has been apparent in Arvinas, Inc. (ARVN) lately. While the stock has lost 14.4% over the past week, it could witness a trend reversal as a hammer chart pattern was formed in its last ...

Arvinas, Inc. (ARVN) closed the last trading session at $7.50, gaining 3.7% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall ...

Arvinas, Inc. (ARVN) shares soared 8.8% in the last trading session to close at $9.03. The move was backed by solid volume with far more shares changing hands than in a normal session.

ARVN has a market cap of $1.78bn and a cash balance of $1.23bn as of June. Including in this figure is the $150mn they received from Novartis ( NVS ) in May as licensing upfront fees for ARV-766.

Barclays analyst Peter Lawson maintained a Buy rating on Arvinas Holding Company (ARVN – Research Report) today and set a price target of $48.00. The company’s shares closed yesterday at $27. ...